第三届哥伦比亚生物仿制药监管评估教育研讨会2019 -报告

Pub Date : 2020-09-15 DOI:10.5639/gabij.2020.0903.022
J. Borg, Yolanda Elias Gramajo, A. Laslop, R. Thorpe, Jian Wang
{"title":"第三届哥伦比亚生物仿制药监管评估教育研讨会2019 -报告","authors":"J. Borg, Yolanda Elias Gramajo, A. Laslop, R. Thorpe, Jian Wang","doi":"10.5639/gabij.2020.0903.022","DOIUrl":null,"url":null,"abstract":"Introduction: Biosimilars have the potential to improve access to medicines for\n many across the globe. However, work is required to ensure adequate regulation,\n pharmacovigilance and education about biosimilars. Colombia implemented biosimilars\n regulation in 2017 and a 3rd Colombian Educational Workshop was organized by GaBI and\n the Instituto Nacional de Vigilancia de Medicamentos y Alimentos (INVIMA) in 2019 to\n follow up on progress and provide a forum for further discussion. Methods: The 3rd\n Colombian Educational Workshop on Regulatory Assessment was held in Bogotá, Colombia on\n 30 April 2019. The format included expert speaker presentations, a panel discussion,\n Q&A sessions and case study workgroup discussions. Participants included regulators,\n clinicians, pharmacists, academics and healthcare professionals from Colombia who are\n involved in biological/ biosimilar medicines evaluation, and expert speakers from\n Canada, Europe and the US. Results: Presentations and topics of discussion included the\n current status of biosimilars regulation in Colombia, how to carry out a quality\n assessment of a biological/biosimilar, pharmacological and clinical studies, and\n extrapolation of indications. Conclusion: The meeting helped to clarify many regulatory\n concepts and concerns, and highlighted Colombia’s initial successes since the\n implementation of its regulatory guidelines. In addition, the meeting acted as a forum\n to exchange knowledge on best practice, and to discuss pharmacovigilance and the future\n plans for education regarding biosimilars in Colombia. Several key action points were\n concluded following the discussions.","PeriodicalId":0,"journal":{"name":"","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"3rd Colombian educational workshop on regulatory assessment of biosimilars 2019 –\\n Report\",\"authors\":\"J. Borg, Yolanda Elias Gramajo, A. Laslop, R. Thorpe, Jian Wang\",\"doi\":\"10.5639/gabij.2020.0903.022\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Introduction: Biosimilars have the potential to improve access to medicines for\\n many across the globe. However, work is required to ensure adequate regulation,\\n pharmacovigilance and education about biosimilars. Colombia implemented biosimilars\\n regulation in 2017 and a 3rd Colombian Educational Workshop was organized by GaBI and\\n the Instituto Nacional de Vigilancia de Medicamentos y Alimentos (INVIMA) in 2019 to\\n follow up on progress and provide a forum for further discussion. Methods: The 3rd\\n Colombian Educational Workshop on Regulatory Assessment was held in Bogotá, Colombia on\\n 30 April 2019. The format included expert speaker presentations, a panel discussion,\\n Q&A sessions and case study workgroup discussions. Participants included regulators,\\n clinicians, pharmacists, academics and healthcare professionals from Colombia who are\\n involved in biological/ biosimilar medicines evaluation, and expert speakers from\\n Canada, Europe and the US. Results: Presentations and topics of discussion included the\\n current status of biosimilars regulation in Colombia, how to carry out a quality\\n assessment of a biological/biosimilar, pharmacological and clinical studies, and\\n extrapolation of indications. Conclusion: The meeting helped to clarify many regulatory\\n concepts and concerns, and highlighted Colombia’s initial successes since the\\n implementation of its regulatory guidelines. In addition, the meeting acted as a forum\\n to exchange knowledge on best practice, and to discuss pharmacovigilance and the future\\n plans for education regarding biosimilars in Colombia. Several key action points were\\n concluded following the discussions.\",\"PeriodicalId\":0,\"journal\":{\"name\":\"\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0,\"publicationDate\":\"2020-09-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5639/gabij.2020.0903.022\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5639/gabij.2020.0903.022","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

生物仿制药有可能改善全球许多人获得药物的机会。然而,需要开展工作,以确保对生物仿制药进行充分的监管、药物警戒和教育。哥伦比亚于2017年实施了生物仿制药法规,GaBI和国家医疗保健和食品监督研究所(INVIMA)于2019年组织了第三届哥伦比亚教育研讨会,以跟进进展并提供进一步讨论的论坛。方法:第三届哥伦比亚监管评估教育研讨会于2019年4月30日在哥伦比亚波哥大举行。会议形式包括专家演讲、小组讨论、问答环节和案例研究工作组讨论。与会者包括来自哥伦比亚参与生物/生物类似药评估的监管机构、临床医生、药剂师、学者和卫生保健专业人员,以及来自加拿大、欧洲和美国的专家演讲者。结果:演讲和讨论的主题包括哥伦比亚生物类似药监管的现状,如何对生物/生物类似药进行质量评估,药理学和临床研究,以及适应症的推断。结论:会议有助于澄清许多监管概念和关注的问题,并强调了哥伦比亚自实施其监管准则以来取得的初步成功。此外,会议还作为交流最佳做法知识的论坛,讨论了哥伦比亚关于生物仿制药的药物警戒和未来教育计划。讨论之后总结了几个关键的行动要点。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
3rd Colombian educational workshop on regulatory assessment of biosimilars 2019 – Report
Introduction: Biosimilars have the potential to improve access to medicines for many across the globe. However, work is required to ensure adequate regulation, pharmacovigilance and education about biosimilars. Colombia implemented biosimilars regulation in 2017 and a 3rd Colombian Educational Workshop was organized by GaBI and the Instituto Nacional de Vigilancia de Medicamentos y Alimentos (INVIMA) in 2019 to follow up on progress and provide a forum for further discussion. Methods: The 3rd Colombian Educational Workshop on Regulatory Assessment was held in Bogotá, Colombia on 30 April 2019. The format included expert speaker presentations, a panel discussion, Q&A sessions and case study workgroup discussions. Participants included regulators, clinicians, pharmacists, academics and healthcare professionals from Colombia who are involved in biological/ biosimilar medicines evaluation, and expert speakers from Canada, Europe and the US. Results: Presentations and topics of discussion included the current status of biosimilars regulation in Colombia, how to carry out a quality assessment of a biological/biosimilar, pharmacological and clinical studies, and extrapolation of indications. Conclusion: The meeting helped to clarify many regulatory concepts and concerns, and highlighted Colombia’s initial successes since the implementation of its regulatory guidelines. In addition, the meeting acted as a forum to exchange knowledge on best practice, and to discuss pharmacovigilance and the future plans for education regarding biosimilars in Colombia. Several key action points were concluded following the discussions.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1